MCT imaging for brain tumors and neuroblastoma
Part of Cancer clinical trials.
This study is for children or young adults already in specific brain tumor or neuroblastoma trials. It looks at how a type of imaging (MCT) might help doctors better understand and treat these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be already enrolled in either the PNOC023 trial (for a type of brain cancer) or the ANBL1531 trial (for high-risk neuroblastoma, a nerve cancer).
- Your cancer must be confirmed by a tissue sample (biopsy).
- Your bone marrow, kidneys, liver, and nervous system must be working well enough (checked by standard tests).
- You must have tumor tissue, blood, and/or spinal fluid samples available for the study.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a radioactive medicine called MIBG to target and kill neuroblastoma or related tumor cells that have not responded to standard treatments. It may help patients whose cancer has come back or is hard to treat.
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
This study compares two types of imaging scans to see which is better at finding neuroblastoma in children. Your child will get both a standard MIBG scan and a newer PET scan, and the results will be compared to help improve future detection.
This trial provides access to a radioactive medicine called 131I-MIBG for people with certain nerve tumors that have returned or not responded to standard treatment. The treatment targets and kills cancer cells, and it may help when other options have not worked.
This trial gives a radioactive drug called 131-I-MIBG to treat neuroblastoma that has not gone away or has come back. The drug targets cancer cells, and stem cells are given back after treatment to help the body recover.
This trial tests a combination of targeted radiation (MIBG) with two medicines, vorinostat and dinutuximab, for children and young adults with high-risk neuroblastoma that has returned or not fully responded to earlier treatment. The goal is to see if adding these medicines helps the radiation work better and improves outcomes.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.